Neurobiological changes mediating the effects of chronic fluoxetine on cocaine use

Neuropsychopharmacology

Volumn 37, Issue 8, 2012, Pages 1816-1824

  Sawyer, Eileen K ^a   Mun, Jiyoung ^b   Nye, Jonathon A ^b   Kimmel, Heather L ^a,b   Voll, Ronald J ^b   Stehouwer, Jeffrey S ^b   Rice, Kenner C ^c   Goodman, Mark M ^b   Howell, Leonard L ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

5HT2A; cocaine; fluoxetine; nonhuman primate; reinstatement; self administration

Indexed keywords

COCAINE; DOPAMINE; FLUOXETINE; PROLACTIN; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER;

ANIMAL EXPERIMENT; ARTICLE; BRAIN STEM; CAUDATE NUCLEUS; DRUG PROTEIN BINDING; DRUG SELF ADMINISTRATION; FEMALE; FRONTAL CORTEX; MALE; MESENCEPHALON; MICRODIALYSIS; NEUROBIOLOGY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROLACTIN RELEASE; REINFORCEMENT; RHESUS MONKEY;

ANIMALS; BRAIN; COCAINE; COCAINE-RELATED DISORDERS; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTINCTION, PSYCHOLOGICAL; FEMALE; FENFLURAMINE; FLUOXETINE; FUNCTIONAL NEUROIMAGING; MACACA MULATTA; MALE; MICRODIALYSIS; POSITRON-EMISSION TOMOGRAPHY; PROLACTIN; RECEPTOR, SEROTONIN, 5-HT2A; SELF ADMINISTRATION; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS;

EID: 84862327523     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.29     Document Type: Article

References (50)

1. Audenaert K, Peremans K, Goethals I, van Heeringen C (2006). Functional imaging, serotonin and the suicidal brain. Acta Neurol Belg 106: 125-131. (Pubitemid 44613872)
2. Baker DA, Tran-Nguyen TL, Fuchs RA, Neisewander JL (2001). Influence of individual differences and chronic fluoxetine treatment on cocaine-seeking behavior in rats. Psychopharmacology (Berl) 155: 18-26. (Pubitemid 32295765)
3. Banks ML, Czoty PW, Gage HD, Bounds MC, Garg PK, Garg S et al (2008). Effects of cocaine and MDMA self-administration on serotonin transporter availability in monkeys. Neuropsychopharmacology 33: 219-225. (Pubitemid 350243361)
4. Baumann P (1996). Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 31: 444-469.
5. Benmansour S, Cecchi M, Morilak DA, Gerhardt GA, Javors MA, Gould GG et al (1999). Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J Neurosci 19: 10494-10501. (Pubitemid 30228055)
6. Brink CB, Viljoen SL, de Kock SE, Stein DJ, Harvey BH (2004). Effects of myo-inositol versus fluoxetine and imipramine pretreatments on serotonin 5HT2A and muscarinic acetylcholine receptors in human neuroblastoma cells. Metab Brain Dis 19: 51-70. (Pubitemid 39005625)
7. Bubar MJ, Cunningham KA (2008). Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse. Prog Brain Res 172: 319-346.
8. Carr GV, Lucki I (2011). The role of serotonin receptor subtypes in treating depression: a review of animal studies. Psychopharmacology (Berl) 213: 265-287.
9. Carroll ME, Lac ST, Asencio M, Kragh R (1990). Fluoxetine reduces intravenous cocaine self-administration in rats. Pharmacol Biochem Behav 35: 237-244. (Pubitemid 20034592)
10. Ceglia I, Acconcia S, Fracasso C, Colovic M, Caccia S, Invernizzi RW (2004). Effects of chronic treatment with escitalopram or citalopram on extracellular 5-HT in the prefrontal cortex of rats: role of 5-HT1A receptors. Br J Pharmacol 142: 469-478. (Pubitemid 38869860)
11. Chaiseha Y, Kang SW, Leclerc B, Kosonsiriluk S, Sartsoongnoen N, El Halawani ME (2010). Serotonin receptor subtypes influence prolactin secretion in the turkey. Gen Comp Endocrinol 165: 170-175.
12. Cunningham KA, Callahan PM (1991). Monoamine reuptake inhibitors enhance the discriminative state induced by cocaine in the rat. Psychopharmacology (Berl) 104: 177-180.
13. Czoty PW, Ginsburg BC, Howell LL (2002). Serotonergic attenuation of the reinforcing and neurochemical effects of cocaine in squirrel monkeys. J Pharmacol Exp Ther 300: 831-837. (Pubitemid 34164986)
14. Filip M, Bubar MJ, Cunningham KA (2006). Contribution of serotonin (5-HT) 5-HT2 receptor subtypes to the discriminative stimulus effects of cocaine in rats. Psychopharmacology (Berl) 183: 482-489. (Pubitemid 41721150)
15. Fletcher PJ, Grottick AJ, Higgins GA (2002). Differential effects of the 5-HT(2A) receptor antagonist M100907 and the 5-HT(2C) receptor antagonist SB242084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding. Neuropsychopharmacology 27: 576-586.
16. Grabowski J, Rhoades H, Elk R, Schmitz J, Davis C, Creson D et al (1995). Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: two placebo-controlled double-blind trials. J Clin Psychopharmacol 15: 163-174.
17. Hinz R, Bhagwagar Z, Cowen PJ, Cunningham VJ, Grasby PM (2007). Validation of a tracer kinetic model for the quantification of 5-HT(2A) receptors in human brain with [(11)C]MDL 100,907. J Cereb Blood Flow Metab 27: 161-172. (Pubitemid 46006594)
18. Howell LL, Wilcox KM (2001a). The dopamine transporter and cocaine medication development: drug self-administration in nonhuman primates. J Pharmacol Exp Ther 298: 1-6. (Pubitemid 32574503)
19. Howell LL, Wilcox KM (2001b). Intravenous drug self-administration in nonhuman primates. In: Buccafusco JJ (ed). Methods of Behavior Analysis in Neuroscience. CRC Press: Boca Raton, FL. pp 91-110.
20. Ito H, Nyberg S, Halldin C, Lundkvist C, Farde L (1998). PET imaging of central 5-HT2A receptors with carbon-11-MDL 100,907. J Nucl Med 39: 208-214. (Pubitemid 28063197)
21. Jorgensen HS (2007). Studies on the neuroendocrine role of serotonin. Dan Med Bull 54: 266-288.
22. Kirkland Henry P, Davis M, Howell LL (2009). Effects of cocaine self-administration history under limited and extended access conditions on in vivo striatal dopamine neurochemistry and acoustic startle in rhesus monkeys. Psychopharmacology (Berl) 205: 237-247.
23. Kish SJ, Furukawa Y, Chang LJ, Tong J, Ginovart N, Wilson A et al (2005). Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? Nucl Med Biol 32: 123-128. (Pubitemid 40260663)
24. Koob GF, Volkow ND (2010). Neurocircuitry of addiction. Neuropsychopharmacology 35: 217-238.
25. Kreiss DS, Lucki I (1995). Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J Pharmacol Exp Ther 274: 866-876.
26. Kugaya A, Seneca NM, Snyder PJ, Williams SA, Malison RT, Baldwin RM et al (2003). Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology 28: 413-420.
27. Lammertsma AA, Hume SP (1996). Simplified reference tissue model for PET receptor studies. Neuroimage 4(3 Part 1): 153-158.
28. Marek GJ, Martin-Ruiz R, Abo A, Artigas F (2005). The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. Neuropsychopharmacology 30: 2205-2215. (Pubitemid 41643971)
29. Mash DC, Staley JK, Izenwasser S, Basile M, Ruttenber AJ (2000). Serotonin transporters upregulate with chronic cocaine use. J Chem Neuroanatomy 20: 271-280. (Pubitemid 32162886)
30. Meyer JH, Kapur S, Eisfeld B, Brown GM, Houle S, DaSilva J et al (2001). The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. Am J Psychiatry 158: 78-85. (Pubitemid 32047250)
31. Moeller FG, Schmitz JM, Steinberg JL, Green CM, Reist C, Lai LY et al (2007). Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial. Am J Drug Alcohol Abuse 33: 367-378. (Pubitemid 47037175)
32. Newman ME, Shapira B, Lerer B (1998). Evaluation of central serotonergic function in affective and related disorders by the fenfluramine challenge test: a critical review. Int J Neuropsychopharmacol 1: 49-69. (Pubitemid 128538366)
33. O'Keane V, O'Hanlon M, Webb M, Dinan T (1991). d-fenfluramine/prolactin response throughout the menstrual cycle: evidence for an oestrogen-induced alteration. Clin Endocrinol (Oxf) 34: 289-292.
34. Oliveto A, Poling J, Mancino MJ, Williams DK, Thostenson J, Pruzinsky R et al (2012). Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms (1). Addiction 107: 131-141.
35. Parsons LH, Justice Jr JB (1993). Serotonin and dopamine sensitization in the nucleus accumbens, ventral tegmental area, and dorsal raphe nucleus following repeated cocaine administration. J Neurochem 61: 1611-1619. (Pubitemid 23317180)
36. Qu Y, Aluisio L, Lord B, Boggs J, Hoey K, Mazur C et al (2009). Pharmacokinetics and pharmacodynamics of norfluoxetine in rats: Increasing extracellular serotonin level in the frontal cortex. Pharmacol Biochem Behav 92: 469-473.
37. Riad M, Rbah L, Verdurand M, Aznavour N, Zimmer L, Descarries L (2008). Unchanged density of 5-HT(1A) autoreceptors on the plasma membrane of nucleus raphe dorsalis neurons in rats chronically treated with fluoxetine. Neuroscience 151: 692-700.
38. Ruedi-Bettschen D, Rowlett JK, Spealman RD, Platt DM (2009). Attenuation of cocaine-induced reinstatement of drug seeking in squirrel monkeys: kappa opioid and serotonergic mechanisms. Psychopharmacology (Berl) 210: 169-177.
39. Sawyer EK, Howell LL (2011). Pharmacokinetics of fluoxetine in rhesus macaques following multiple routes of administration. Pharmacology 88: 44-49.
40. Schama KF, Howell LL, Byrd LD (1997). Serotonergic modulation of the discriminative-stimulus effects of cocaine in squirrel monkeys. Psychopharmacology (Berl) 132: 27-34. (Pubitemid 27303736)
41. Schmitz JM, Averill P, Stotts AL, Moeller FG, Rhoades HM, Grabowski J (2001). Fluoxetine treatment of cocaine-dependent patients with major depressive disorder. Drug Alcohol Depend 63: 207-214. (Pubitemid 32545407)
42. Smith TD, Kuczenski R, George-Friedman K, Malley JD, Foote SL (2000). In vivo microdialysis assessment of extracellular serotonin and dopamine levels in awake monkeys during sustained fluoxetine administration. Synapse 38: 460-470.
43. Stehouwer JS, Jarkas N, Zeng F, Voll RJ, Williams L, Camp VM et al (2008). Synthesis, radiosynthesis, and biological evaluation of fluorine-18-labeled 2beta-carbo(fluoroalkoxy)-3beta-(3′-((Z)-2- haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. J Med Chem 51: 7788-7799.
44. Substance Abuse and Mental Health Services Administration (2010). Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings. (Office of Applied Studies, NSDUH Series H-38A, HHS Publication No SMA 10-4586 Findings) Rockville, MD.
45. Tanner MJ, Hadlow NC, Wardrop R (2011). Variation of female prolactin levels with menopausal status and phase of menstrual cycle. Aust N Z J Obstet Gynaecol 51: 321-324.
46. Van Oekelen D, Luyten WH, Leysen JE (2003). 5-HT2A and 5-HT2C receptors and their atypical regulation properties. Life Sci 72: 2429-2449. (Pubitemid 36321816)
47. Walsh SL, Preston KL, Sullivan JT, Fromme R, Bigelow GE (1994). Fluoxetine alters the effects of intravenous cocaine in humans. J Clin Psychopharmacol 14: 396-407. (Pubitemid 24378141)
48. Winstanley EL, Bigelow GE, Silverman K, Johnson RE, Strain EC (2011). A randomized controlled trial of fluoxetine in the treatment of cocaine dependence among methadone-maintained patients. J Subst Abuse Treat 40: 255-264.
49. Wong DT, Bymaster FP, Engleman EA (1995). Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci 57: 411-441.
50. Yamauchi M, Miyara T, Matsushima T, Imanishi T (2006). Desensitization of 5-HT2A receptor function by chronic administration of selective serotonin reuptake inhibitors. Brain Res 1067: 164-169. (Pubitemid 43133085)